Potency of Omadacycline against Mycobacteroides abscessus Clinical Isolates In Vitro and in a Mouse Model of Pulmonary Infection-Reference-Cited by-同舟云学术

Potency of Omadacycline against Mycobacteroides abscessus Clinical Isolates In Vitro and in a Mouse Model of Pulmonary Infection

Published:2022-01-18 Issue:1 Volume:66 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Nicklas Danielle A.¹,Maggioncalda Emily C.¹,Story-Roller Elizabeth¹,Eichelman Benjamin¹,Tabor Chavis¹,Serio Alisa W.²,Keepers Tiffany R.²,Chitra Surya²,Lamichhane Gyanu¹^ORCID

Affiliation:

1. Division of Infectious Diseases, Department of Medicine, School of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

2. Paratek Pharmaceuticals, Inc., King of Prussia, Pennsylvania, USA

Abstract

The incidence of nontuberculous mycobacterial diseases in the United States is rising and has surpassed that of tuberculosis. Most notable among the nontuberculous mycobacteria is Mycobacteroides abscessus , an emerging environmental opportunistic pathogen capable of causing chronic infections. M. abscessus disease is difficult to treat, and the current treatment recommendations include repurposed antibiotics, several of which are associated with undesirable side effects.

Funder

Paratek Pharmaceuticals

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01704-21

Reference68 articles.

1. Phylogenomics and Comparative Genomic Studies Robustly Support Division of the Genus Mycobacterium into an Emended Genus Mycobacterium and Four Novel Genera

2. Mycobacterium abscessus: a new antibiotic nightmare

3. Mycobacterium abscessus: Environmental Bacterium Turned Clinical Nightmare